
Lonza has pushed further into the high-potency active pharmaceutical ingredient (HPAPI) sector with another round of investment at its manufacturing …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

